The survey, conducted from June 26 to 29, collected responses from 1,020 likely voters with a margin of error of plus or minus 3.9 percent. The national sentiment shows former President Donald Trump maintaining a strong lead with 49 percent support, while Florida Gov. Ron DeSantis following far behind with 16 percent support and Ramaswamy securing a close third place with 10 percent.
The Echelon Insights survey revealed that no other candidate has reached double-digit support. Former Vice President Mike Pence and former South Carolina Gov. Nikki Haley are tied with five percent support followed by South Carolina Sen. Tim Scott with four percent support. Former New Jersey Gov. Chris Christie has two percent support, while both North Dakota Gov. Doug Burgum and Miami Mayor Francis Suarez have one percent support.
The survey results also showed Ramaswamy in third place in battleground states. Trump maintained a majority of support with 56 percent, followed by DeSantis with 22 percent and Ramaswamy with seven percent. (Related: RFK Jr.'s favorability rating rises as Biden's satisfaction rating drops in separate polls.)
Ramaswamy's recent surge in popularity can be attributed to increased name recognition and favorability among Republican primary voters, as indicated by Morning Consult's weekly survey. The businessman has gained attention by challenging his fellow presidential candidates to commit to pardoning Trump for federal charges on their first day in office.
On June 13, Ramaswamy took to social media to make his challenge, writing: "I challenge every U.S. Presidential candidate to join me in standing for TRUTH. Commit to pardon Donald Trump for these federal charges on Day 1, or explain why you won't."
His call has sparked discussions and debate among the candidates, further boosting his visibility and appeal.
Ramaswamy predicted in April that he would top the GOP primary
Back in April, Ramaswamy confidently made predictions about his chances in the GOP primary for the 2024 presidential race. According to a memo from Politico Playbook, Ramaswamy's campaign believes that he will be polling in second or third place by the end of 2023. This would position him as a viable alternative to Trump or DeSantis.
Ben Yoho, the CEO of Vivek 2024, expressed confidence in the candidacy of Ramaswamy, stating that Republican voters will seek an outsider who embraces the pro-Trump and America First agenda, particularly as Trump and DeSantis engage in what he called self-destructive behavior throughout the summer and fall. Yoho also highlighted Ramaswamy's strong campaign finances and claimed that the businessman is polling competitively with well-known national political figures.
However, previous polling data from RealClear Politics did not fully support their claims. RealClearPolitics put Ramaswamy's average support across different polls at 1.5 percent, putting him in sixth place among 11 potential GOP presidential candidates. Trump, DeSantis, Pence, Haley and Scott all outperform Ramaswamy.
Yoho dismissed other candidates such as Haley and former Arkansas Gov. Asa Hutchinson as "career politicians" and claimed that only Ramaswamy, Trump and DeSantis have the profile, message and resources to be competitive in the early primary states. Yoho argued that the status of Ramaswamy as an outsider provides an advantage over his opponents.
Despite the previous polling numbers, Yoho believes Ramaswamy's outsider appeal and substantial campaign funds, reportedly on par with Trump's, would propel him to victory. Yoho said the primary would eventually come down to a choice between Trump and the "memories of America First 1.0" or Ramaswamy and the "promise of America First 2.0."
Learn more about the race for the Republican Party's nomination at VoteRepublican.news.
Watch this interview with Vivek Ramaswamy as he explains his plan, if elected, to revive record-low American patriotism.
More related stories:
Not a bad idea: GOP presidential candidate Vivek Ramaswamy wants to SHUT DOWN the FBI and start over.
LinkedIn censors presidential candidate who says fossil fuels ‘required for prosperity.’
Sources include:
Please contact us for more information.
over 1 year ago
The U.S. is infested with heathens, you don't need one as President.
over 1 year ago
This came from Wikipedia (sorry about that) but appears factual: In 2015, Ramaswamy raised $360 million for the Roivant subsidiary Axovant Sciences in an attempt to market intepirdine as a drug for Alzheimer's disease.[20][22] In December 2014,[23] Axovant purchased the patent for intepirdine from GlaxoSmithKline (where the drug had failed four previous clinical trials) for $5 million, a small sum in the industry.[21] Ramaswamy appeared on the cover of Forbes magazine in 2015, and said his company would "be the highest return on investment endeavor ever taken up in the pharmaceutical industry."[21][22] Before new clinical trials began, he engineered an initial public offering in Axovant.[21] Axovant became a "Wall Street darling" and raised $315 million in its IPO.[23] The company's market value initially soared to almost $3 billion, although at the time it only had eight employees, including Ramaswamy's brother and mother.[21] Ramaswamy took a massive payout after selling a portion of his shares in Roivant to Viking Global Investors.[21] He claimed more than $37 million in capital gains in tax year 2015.[21]Ramaswamy said his company would be the "Berkshire Hathaway of drug development"[1] and touted the drug as a "tremendous" opportunity that "could help millions" of patients, prompting some criticism that he was overpromising.[21]
In September 2017, the company announced that intepirdine had failed in its large clinical trial.[21][24] The company's value plunged; it lost 75% in one day, and continued to decline afterward.[21] Shareholders who lost money included various institutional investors, as well as the California State Teachers' Retirement System pension fund.[21] Ramaswamy was insulated from much of Axovant's losses, because he held his personal stake through Roivant.[21][23] The company abandoned intepirdine. Ramaswamy said in 2018 had no regrets about the way the company had handled the drug;[23] in subsequent years, he said that he regretted the outcome, but was annoyed by criticism of the company.[21] Axovant attempted to reinvent itself as a gene therapy company,[25] but dissolved in 2023.[21]
over 1 year ago
My post failed to post twice, so I am breaking it down.
I really question his background for being in the likes of Vanguard, State Street, and BlackRock. I would be careful of anyone with ties to The Squid and Wall Street. We're supposed to believe he's some kind of boy wonder, but his bio reads like a slick, fast talker. I'm concerned the plan was to put him in the good graces of sincere people like Kathy Barnette and wonder if she was allowed media time with the plan of latter using her popularity to unwittingly later promote him.
over 1 year ago
What about also pardoning Julian Assange on Day 1?